Author:
Guan Huan-yu,Li Peng-fei,Wang Xiao-ming,Yue Jia-jing,He Yang,Luo Xiao-mei,Su Mei-feng,Liao Shang-gao,Shi Yue
Funder
National Natural Science Foundation of China
Beijing Municipal Natural Science Foundation
Subject
Pharmacology (medical),Pharmacology
Reference38 articles.
1. New approaches to prevent intestinal toxicity of irinotecan-based regimens;Alimonti;Cancer Treat. Rev,2004
2. Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11;Araki;Jpn. J. Cancer Res,1993
3. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats;Arimori;Pharm. Res,2003
4. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats;Bansal;Eur. J. Pharm. Sci,2009
5. Development and validation of an UPLC-MS/MS method for the quantification of irinotecan, SN-38 and SN-38 glucuronide in plasma, urine, feces, liver and kidney: application to a pharmacokinetic study of irinotecan in rats;Basu;J. Chromatogr. B Analyt. Technol. Biomed. Life Sci,2016
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献